한빛사 인터뷰
- 등록2024-02-20
- 조회1,044
1. Can you please briefly summarize the paper?
Adoptive T cell therapies have produced spectacular results in multiple treatment-related diseases. However, they have failed to make a significant impact on solid tumors, which represent >90% of all adult cancers. Solid tumors have an immunosuppressive microenvironment that limits T cell persistence and potency. To overcome this barrier and address the important clinical unmet need, we turned to extranodal T cell lymphomas, which develop mutations that increase T cell fitness in analogous microenvironments. We screened 71 mutations in vitro to assess their effects on signaling and in vivo to assess their effects on persistence. Collectively, we found one, CARD11-PIK3R3, which increases T cell potency >100 times enabling safe and durable cures of multiple models of skin, lung, and blood cancers in mouse models. We are building upon this discovery to make next-generation adoptive T cell therapies.
2. Can you please tell us the main difficulties you had in the laboratory work and how you overcame them?
This was a new area to us, so we had to learn by reading and thinking about the problem. We also had outstanding collaborators who helped us to actualize our vision.
3.Please introduce your laboratory, university or organization to bio-researchers in Korea.
My laboratory is interested in following natural experiments. By studying samples from human patients we can deploy high dimensional approaches to identify molecular causes of disease. We are now utilizing this approach to rationally design novel therapies for a number of immune related diseases including cancer (the subject of this paper) and autoimmune disease (the subject of another paper that was just accepted to Nature last week). Our lab is in a beautiful part of Chicago in the USA. We have three postdoctoral fellows, 6 graduate students, and a number of technicians. Our lab is smart, kind, and ambitious.
4. Please tell us your experiences and your thoughts related to research activities abroad.
I have never trained in Korea. However, through my experience at Harvard, Yale, and now Northwestern, I like the academic environment here. IT teaches you how to think, how to write, and how to discuss science.
5. Can you provide some advice for younger scientists who have plans to study abroad?
Be ambitious and optimistic.
6. Future plan?
We are working on developing novel potential cures for cancer and autoimmune disease.
7. Do you have anything else that you would like to tell Korean scientists and students?
Please consider joining our lab. (https://choilaboratory.northwestern.edu/)
#Cancer immunology
# CAR T
# immune engineering
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
